Optibrium Partners with TalTech on EU-Funded PhD Programme to Advance Sustainable Drug Discovery

The research will focus on developing faster and more accurate methods for predicting drug metabolism

PHARMASEAL and Viedoc Announce a Technical Integration Partnership

PHARMASEAL, provider of the Engility® Trial Management Platform consisting of a Clinical Trial Management System (CTMS) CTMS and Electronic Trial Master File (eTMF), has announced a Technology Integration Partnership with Viedoc, a global leader in Electronic Data Capture (EDC) and eClinical technologies. This collaboration integrates PHARMASEAL’s advanced CTMS platform with Viedoc’s cutting-edge EDC capabilities, including its flagship product Viedoc Clinic, to deliver a more integrated solution for life science companies managing clinical trials worldwide.

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Femasys has received regulatory approvals in Australia and New Zealand for its innovative infertility solutions—FemaSeed®, a first-line, intratubal insemination treatment, and FemVue®, a diagnostic tool for assessing fallopian tube patency. These approvals mark a strategic expansion of the company’s global footprint and further validate its mission to offer more accessible, less invasive, and cost-effective fertility care. With FemaSeed shown to more than double pregnancy rates over traditional IUI in clinical trials, and FemVue enabling real-time fertility diagnostics in-office, this milestone offers new hope to patients facing infertility and strengthens Femasys’ commercial potential in international markets.

ZeOmega and MedeAnalytics Unveil Joint Population Health Solution to Accelerate Value-Based Care

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Gene by Gene Supports Landmark Pharmacogenomics Trial to Personalize Prescribing in NHS Scotland

Gene by Gene Supports Landmark Pharmacogenomics Trial to Personalize Prescribing in NHS Scotland

Dr Quin Wills Appointed as Ochre Bio CEO

Oxford-based Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed Dr Quin Wills as CEO.

Takara Bio Europe signs distribution agreement with MACHEREY-NAGEL to expand access to high-quality bioanalysis products

Takara Bio Europe is pleased to announce it has entered into a distribution agreement with MACHEREY-NAGEL to expand access to high-quality bioanalysis products.

Spartanburg Regional Healthcare System (SRHS) Deploys 2bPrecise Enterprise

PharmaForceIQ Announces Substantial Growth as it Expands Optichannel Engagement Solutions

PharmaForceIQ has announced a period of significant growth as it goes beyond omnichannel to optichannel campaign solutions. The company is the fastest growing independent provider of precision customer engagement technologies for the Life Science industry, and it has experienced a multifold increase in average contract value in the past year. In one client, the company expanded from a pilot campaign for one specialty brand to their entire specialty pharmaceutical portfolio in only 7 months. PharmaForceIQ also has a 100% client renewal rate – demonstrating that its data-driven strategies deliver unmatched efficiency and tangible results

Rewriting the Timeline of Detection: Linus Health's Digital Platform Uncovers the Earliest Signs of Cognitive Decline

Rewriting the Timeline of Detection: Linus Health's Digital Platform Uncovers the Earliest Signs of Cognitive Decline

Laverock Therapeutics expands seed funding and announces key milestone progress

Laverock Therapeutics closes additional seed funding round, bringing total raised to more than £20m, and announces key data

Baylor Genetics Applauds New Guidance from American Academy of Pediatrics for Genome and Exome Sequencing to be used as First-Tier Tests for Children with Certain Developmental Delays

Baylor Genetics, a leading clinical diagnostic laboratory at the forefront of genetic testing, today announced its support for the American Academy of Pediatrics’ (AAP) updated guidance recommending whole genome and whole exome sequencing as first-tier tests. Baylor Genetics has long recognized the value of these tests, and offers a comprehensive, structured framework to help pediatricians promptly identify potential genetic causes in children presenting with global developmental delay (GDD) or intellectual disability (ID). This milestone empowers pediatricians, supported by genetics professionals, with access to earlier and more comprehensive insights that guide clinical decisions for patients and their families, marking a critical step toward faster diagnoses and improved outcomes.

InSysBio to announce extension of collaboration with discoveric bio alpha

The project aims at translational mechanistic modeling of antibodies to predict human pharmacokinetics and target occupancy in cerebrospinal fluid

Alithea Genomics Announces the Launch of MERCURIUS™ FLASH-seq: A Plate-Based, Full-Length Single Cell RNA-seq Kit Delivering Exceptional Sensitivity and Simplicity

Alithea Genomics has announced the commercial launch of MERCURIUS™ FLASH-seq, a next-generation library preparation kit for full-length single-cell RNA sequencing.

Insilico Medicine Completes First-in-Patient Dosing of ISM3412, the Novel MAT2A Inhibitor for the Treatment of Locally Advanced/​Metastatic Solid Tumors

ISM3412 was designed with the support of Chemistry42, Insilico’s proprietary generative chemistry engine, for the treatment of locally advanced and metastatic solid tumors. The Phase I study of ISM3412 is currently recruiting in multiple sites across the United States and China, aiming to evaluate the safety, tolerability, PK/PD profiles and preliminary efficacy in patients.

Ambience Healthcare's "Patient Recap" Offers Clinicians the First Chart Summarization Technology from an Ambient AI Platform

ResultsCX Earns Great Place To Work® Certification™ in Seven Countries, Including First Time Recognition in India and the UK

Phastar appoints Industry Veteran Billy Amzal as Head of Strategic Consulting

Phastar, a global specialist biometrics & data science Contract Research Organization (CRO), today announced the appointment of Billy Amzal as Head of Strategic Consulting.

Association for Molecular Pathology Publishes Best Practice Recommendations for Clinical HRD Testing

AMP recently published a new report with 12 best practice recommendations focused on the design and validation of clinical HRD assays. To develop these recommendations, AMP assembled an expert panel that included organizational representation from ACCC, ASCO, and the CAP.